Table 1

Demographic details of 30 patients with pulmonary arterial hypertension investigated for circulating growth/differentiation factor 15 (GDF-15) levels and muscle loss

Age46.8 (±13.9) years
Height167 (±8) cm
Weight67.3 (58.8–77.7) kg
 Congenital heart disease7
 RVSP88.5 (±26.8) mm Hg
 TAPSE1.80 (±1.33) mm
 TR velocity408 (±84) cm/s
 PAcT83.8 (±26.5) ms
Exercise, WHO, BNP, GDF-15
 6MWD373 (±126) m
 6MWD % predicted60.5 (±19.0) %
 WHO I: II: III3: 19: 8
 BNP131 (44, 271) pg/mL
 GDF-15862 (459, 1635) pg/mL
  • The table presents data as mean and SD or median and IQR dependent on the distribution of the data.

  • 6MWD, 6 min walk distance; BNP, brain natriuretic peptide; GDF-15, growth/differentiation factor 15; IPAH, idiopathic pulmonary arterial hypertension; PAcT, pulmonary artery acceleration time; RVSP, right ventricular systolic pressure (measured by echocardiogram); TAPSE, tricuspid anterior posterior systolic excursion; TR, tricuspid regurgitation; WHO, WHO functional status.